SFJ plays hard­ball, de­mands rights to Phase­Bio's lead can­di­date

More than two and a half years af­ter back­ing Phase­Bio in de­vel­op­ing a drug that can re­verse a spe­cif­ic blood thin­ner, Cal­i­for­nia-based SFJ Phar­ma­ceu­ti­cals is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER